Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Anacor Pharmaceuticals Inc. (NASDAQ: ANAC) shares spiked 4.96 percent to close at $21.16 a share Friday. The stock traded between $20.35 and $21.50 on volume 480,646 shares traded. The company reported revenues were $8.5 million for the fourth quarter of 2013, compared to $3.3 million a year ago. Shares of Anacor Pharmaceuticals are up approximately 26.0 percent year-to-date.
Get more information on Anacor Pharmaceuticals and free access to the in-depth equity report at: www.FiveStarEquities.com/ANAC
Gilead Sciences, Inc. (NASDAQ: GILD) shares fell 3.79 percent to close at $75.05 a share Friday. The stock traded between $74.5 and $77.10 on volume 18.78 million shares traded. Idenix Pharmaceuticals Inc. has filed a patent infringement lawsuit against the company in France, Germany and the United Kingdom. Shares of Gilead Sciences are down approximately 0.10 percent year-to-date.
Get more information on Gilead Sciences free access to the in-depth equity report at: www.FiveStarEquities.com/GILD
Hologic, Inc. (NASDAQ: HOLX) shares declined 0.05 percent to close at $21.49 a share Friday. The stock traded between $21.32 and $21.77 on volume of 2.17 million shares traded. The company has named former Johnson & Johnson executive Eric Compton as Chief Operating Officer. Shares of Hologic are down approximately 4.0 percent year-to-date.
Get more information on Hologic and free access to the in-depth equity report at: www.FiveStarEquities.com/HOLX
Raptor Pharmaceutical Corp. (NASDAQ: RPTP) shares dropped 23.94 percent to close at $11.25 a share Friday. The stock traded between $11.21 and $14.00 on volume of 6.23 million shares traded. The company reported a larger-than-expected net loss of $12.1 million, or $0.20 per share, for the fourth quarter of 2013. Shares of Raptor Pharmaceutical are down approximately 13.0 percent year-to-date.
Get more information on Raptor Pharmaceutical and free access to the in-depth equity report at: www.FiveStarEquities.com/RPTP
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact: Five Star Equities [email protected]